Methods of treating psoriasis using il-17 antagonists

Abstract

The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.

1 . A method of treating moderate to severe plaque-type psoriasis in adult patients who are candidates for systemic therapy using an IL-17 antagonist, wherein the method comprises:
 a) administering about 75 mg to about 300 mg of the IL-17 antagonist subcutaneously to a patient in need thereof by an induction regimen every two weeks or every three weeks during the first 12 weeks of treatment; and   b) thereafter administering a maintenance dose of about 75 mg to about 300 mg of the IL-17 antagonist subcutaneously to the patient during a maintenance regimen by (i) a continuous monthly treatment, or (ii) an intermittent dosing at start of relapse,   
       wherein the IL-17 antagonist is a monoclonal IL-17 antibody that specifically binds to IL-17A. 
     
     
         2 . The method according to  claim 1 , wherein the IL-17 antibody binds to an epitope of IL-17 comprising Ala79, Asp80, Tyr85, His86, Met87, Asn88. 
     
     
         3 . The method according to  claim 1 , wherein the maintenance regimen comprises treating the patient with a maintenance dose of about 75 mg to about 150 mg of the IL-17 antibody. 
     
     
         4 . The method of  claim 3 , wherein the maintenance regimen comprises treating the patient with a maintenance dose of about 80 mg of the IL-17 antibody. 
     
     
         5 . A method of treating moderate to severe plaque-type psoriasis in a patient weighing greater than 50 kg using an IL-17 antagonist, wherein the method comprises:
 a) administering an initial dose of about 75 mg to about 300 mg of the IL-17 antagonist subcutaneously to the patient; and   b) thereafter administering a maintenance dose of about 75 mg to about 300 mg of the IL-17 antagonist subcutaneously to the patient during a maintenance regimen by (i) a continuous monthly treatment, or (ii) an intermittent dosing at start of relapse,   
       wherein the IL-17 antagonist is a monoclonal IL-17 antibody that specifically binds to IL-17A. 
     
     
         6 . The method of  claim 5 , wherein the initial dose comprises about 160 mg of the IL-17 antibody, and wherein the maintenance dose comprises about 80 mg of the IL-17 antibody. 
     
     
         7 . The method according to  claim 5 , wherein the IL-17 antibody binds to an epitope of IL-17 comprising Ala79, Asp80, Tyr85, His86, Met87, Asn88. 
     
     
         8 . A method of treating moderate to severe plaque-type psoriasis in a patient weighing less than 50 kg using an IL-17 antagonist, wherein the method comprises:
 a) administering an initial dose of about 25 mg to about 300 mg of the IL-17 antagonist subcutaneously to the patient; and   b) thereafter administering a maintenance dose of about 25 mg to about 300 mg of the IL-17 antagonist subcutaneously to the patient during a maintenance regimen by (i) a continuous monthly treatment, or (ii) an intermittent dosing at start of relapse,   
       wherein the IL-17 antagonist is a monoclonal IL-17 antibody that specifically binds to IL-17A. 
     
     
         9 . The method of  claim 8 , wherein the initial dose comprises about 25 mg to about 175 mg of the IL-17 antibody, and wherein the maintenance dose comprises about 20 mg to about 50 mg of the IL-17 antibody. 
     
     
         10 . The method according to  claim 8 , wherein the patient weighs between 25 to 50 kg, wherein the initial dose comprises 80 mg of the IL-17 antibody, and wherein the maintenance dose comprises 40 mg of the IL-17 antibody. 
     
     
         11 . The method according to  claim 8 , wherein the patient weighs less than 25 kg, wherein the initial dose comprises 40 mg of the IL-17 antibody, and wherein the maintenance dose comprises 20 mg of the IL-17 antibody. 
     
     
         12 . The method according to  claim 8 , wherein the IL-17 antibody binds to an epitope of IL-17 comprising Ala79, Asp80, Tyr85, His86, Met87, Asn88.